New hope for Tough-to-Treat stomach tumors
NCT ID NCT05245968
Summary
This early-stage study is testing the safety and effectiveness of a new drug, TAS-116, when given alongside the standard drug imatinib. It is for people with advanced gastrointestinal stromal tumors (GIST) whose cancer has continued to grow despite taking imatinib. The goal is to see if this combination can better control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Health
Melbourne, Australia
-
Beijing Cancer Hospital
Beijing, China
-
Flinders Medical Center
Adelaide, Australia
-
Fudan University, Shanghai Cancer Center
Shanghai, China
-
Hokkaido University Hospital
Hokkaido, Japan
-
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
-
Kumamoto University Hospital
Kumamoto, Japan
-
Linkou Chang Gung Memorial Hospital
Linkou District, Taiwan
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Hospital East
Chiba, Japan
-
National University Cancer Institute
Singapore, Singapore
-
Osaka University Hospital
Osaka, Japan
-
Taipei Veterans General Hospital
Taipei, Taiwan
-
The Cancer Institute Hospital of JFCR
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.